ARTELO BIOSCIENCES, INC. (ARTL) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-15

Key Insights

Artelo terminated its At-The-Market (ATM) offering agreement with R.F. Lafferty effective May 18, 2026, ending a $6.5 million equity offering program that was only 7% utilized ($451,526.95 of $6.5 million raised through 50,858 shares).
The low utilization rate of the ATM facility suggests weak investor demand for Artelo's equity or management's decision that market conditions were unfavorable, indicating potential challenges in the company's market perception or capital position.
Termination of the ATM offering removes a dilution mechanism but also signals the company may have exhausted its near-term capital raising needs or is pivoting to alternative financing strategies, warranting monitoring of future capital requirements.

Want the newest filings?

This analysis covers the filing from 2026-05-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-07

Artelo Biosciences, Inc. has regained compliance with Nasdaq's listing requirements for stockholders' equity and holding an annual shareholder meeting.
The company will be subject to a mandatory panel monitor for one year, during which time it cannot provide a plan of compliance or be granted additional time if it falls out of compliance with the equity rule again.
Failure to maintain compliance during the monitoring period could result in the company's stock being delisted from Nasdaq, requiring them to seek a new hearing and potentially face delisting.

Filed: 2026-03-26

Artelo Biosciences entered into a $315,000 promissory note with Labrys Fund II, L.P., which provides the company with additional working capital to support its business development and operations.
The note has a 12-month maturity and includes conversion rights for Labrys to convert the outstanding balance into Artelo's common stock at a 25% discount to the average of the two lowest closing bid prices over the prior 10 trading days.
Artelo also announced a strategic expansion opportunity for its ART27.13 compound to explore its potential in muscle preservation for patients undergoing glucagon-like peptide-1 receptor agonist therapy.

Filed: 2026-03-18

Artelo Biosciences, Inc. has entered into two securities purchase agreements to issue $237,300 and $113,000 in 12% bridge notes to Vanquish Funding Group Inc. and Boot Capital LLC, respectively, for general working capital purposes.
The notes have a maturity date of January 15, 2027 and can be prepaid by the company at any time with no penalty.
The notes contain a default provision where the principal, interest, and default interest may become due and payable at 150% of the outstanding balance upon an event of default, and the buyers have the right to convert the notes into common stock of the company.

Filed: 2026-03-06

Artelo Biosciences, Inc. has effected a 1-for-3 reverse stock split to improve the marketability and liquidity of its common stock.
The reverse split reduces the total number of outstanding shares from 2,124,772 to approximately 708,258, and the number of authorized shares from 500,000,000 to 166,666,667.
The reverse split is being executed without shareholder approval, as the board of directors has the authority to do so under Nevada law when the number of authorized and outstanding shares are proportionally reduced.

Filed: 2026-02-05

Artelo Biosciences received an exception from Nasdaq to cure its listing deficiencies, including regaining compliance with the $2.5 million stockholders' equity requirement and holding its annual shareholder meeting.
The company has until March 30, 2026, to demonstrate compliance with the stockholders' equity rule by filing a public disclosure on the transactions undertaken to achieve compliance.
While the company intends to take measures to regain compliance, there is no assurance it will be able to do so or maintain compliance with Nasdaq's continued listing requirements.

Filed: 2026-02-05

Artelo Biosciences has entered into a $50 million equity purchase agreement with Square Gate Capital Master Fund, which provides the company with additional funding to support its operations.
The agreement allows Artelo to sell up to $25 million in shares to Square Gate, with an option to increase the commitment by another $25 million.
Artelo has agreed to file a registration statement within 30 days and have it declared effective within 60 days to register the resale of the shares issued to Square Gate.

Filed: 2026-01-30

Artelo Biosciences held its annual shareholder meeting on January 30, 2026, with approximately 50.4% of outstanding shares represented.
Shareholders re-elected two Class II directors, Douglas Blayney, M.D. and Connie Matsui, to serve until the 2028 annual meeting.
Shareholders approved the company's executive compensation and ratified the appointment of Malone Bailey LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Filed: 2026-01-16

Artelo Biosciences, Inc. failed to hold its 2025 annual meeting of stockholders by the required deadline, potentially putting its Nasdaq listing at risk.
The company is working to regain compliance with Nasdaq's listing rules, including holding the delayed annual meeting and addressing a prior deficiency in minimum stockholders' equity.
The outcome of the company's appeal and Nasdaq hearings will be crucial in determining whether it can maintain its Nasdaq listing.

Filed: 2026-01-02

Artelo Biosciences, Inc. (ARTL) has adjourned its 2025 annual meeting of stockholders due to insufficient votes to constitute a quorum, indicating potential shareholder engagement or proxy voting issues.
The company plans to reconvene the annual meeting on January 30, 2026, providing additional time for shareholders to vote on proposals, including a new proposal to ratify the appointment of the independent auditor.
The delayed annual meeting and the need to file supplemental proxy materials suggest potential operational or financial challenges that may be of concern to investors.

Other reports for ARTELO BIOSCIENCES, INC.

Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.